☆ 4.3 Letter

Smoothened inhibitor erismodegib combined with nilotinib in patients with chronic myeloid leukemia resistant/intolerant to at least one prior tyrosine kinase inhibitor: a phase 1b study

LEUKEMIA & LYMPHOMA (2021)

Get Full Text
Add to Collection

Journal

LEUKEMIA & LYMPHOMA
Volume 62, Issue 3, Pages 739-742

Publisher

TAYLOR & FRANCIS LTD
DOI: 10.1080/10428194.2020.1839649

Keywords

-

Categories

Oncology Hematology

Funding

  1. Novartis Pharmaceuticals, AG, Basel

Ask authors/readers for more resources

Protocol

Community support

Reagent

Community support

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.3
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available
Webinars Posters Questions Hubs Funding Journals Papers Connect Collections Reviewers About Us FAQs Mobile App Privacy Policy Terms of Use
© Peeref 2019-2024. All rights reserved.